Pharma5 Announces Morocco’s First Therapeutic Cannabis Medication
Pharma5 to Launch Morocco’s First 100% Local Medicinal Cannabis Drug
The pharmaceutical company Pharma5 is preparing to take a significant step in developing a medical cannabis sector in Morocco. The group has announced the launch of the first 100% Moroccan medication that uses therapeutic cannabis, aimed at treating certain severe forms of epilepsy that are resistant to conventional treatments.
The First Pharmaceutical Active Substance Compliant with European Standards
To introduce this advancement, Pharma5 will host a conference in Casablanca on November 12. The event will be dedicated to unveiling the first pharmaceutical active substance derived from cannabis that has been fully developed in Morocco and complies with European pharmacopoeia standards.
This announcement represents a new milestone in promoting the legal cannabis industry in Morocco, particularly through the development of pharmaceutical products that meet quality standards and regulatory requirements in the sector.
A Generic Drug for Severe Forms of Epilepsy
On this occasion, the laboratory will also present what it claims to be the first 100% Moroccan medication made from therapeutic cannabis. This drug is intended for the treatment of certain severe forms of pharmacoresistant epilepsy—cases of the condition that do not respond adequately to standard treatments.
According to Pharma5, this medication marks the first generic version of the globally recognized treatment in this category.
Through this initiative, the group aims to contribute to the development of a Moroccan pharmaceutical industry based on the local transformation of medical cannabis, while also opening up new avenues for research and drug production in Morocco.
